Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Tumors × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 372 Colorectal Neoplasms 279 Rectal Neoplasms 204 Stomach Neoplasms 190 Pancreatic Neoplasms 120 Neoplasm Metastasis 114 Colonic Neoplasms 83 Neoplasms 81 Triple Negative Breast Neoplasms 56 Esophageal Neoplasms 52 Nasopharyngeal Carcinoma 34 Biliary Tract Neoplasms 34 Cholangiocarcinoma 30 Adenocarcinoma 29 Gallbladder Neoplasms 28 Carcinoma, Hepatocellular 25 Bile Duct Neoplasms 20 Adenocarcinoma Of Esophagus 20 Locally Advanced Rectal Cancer 18 Brain Neoplasms 18 Carcinoma, Non-Small-Cell Lung 16 Squamous Cell Carcinoma of Head and Neck 15 Head and Neck Neoplasms 15 Gastrointestinal Neoplasms 15 Colorectal Cancer Metastatic 15 Liver Neoplasms 14 Esophageal Squamous Cell Carcinoma 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Ovarian Neoplasms 12 Carcinoma, Renal Cell 12

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡